Teerasit Techawiwattanaboon1,2
Thomas Courant3
Livia Brunner3
Suwitra Sathean-anan-kun1,2Pratomporn Krangvichian2,4Nutta Iadsee2,4Yaowarin Nakornpakdee5Noppadon Sangjun6Pat Komanee6Nicolas Collin3Kiat Ruxrungtham2
Kanitha Patarakul1,2*- 1Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- 2Chula Vaccine Research Center (Chula VRC), Center of Excellence in Vaccine Research and Development, Chulalongkorn University, Bangkok, Thailand
- 3Vaccine Formulation Institute, Plan-Les-Ouates, Switzerland
- 4Medical Microbiology, Interdisciplinary Program, Graduate School, Chulalongkorn University, Bangkok, Thailand
- 5Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok, Thailand
- 6Laboratory Animal Section, Analysis Division, Armed Force Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand
By Techawiwattanaboon T, Courant T, Brunner L, Sathean-anan-kun S, Krangvichian P, Iadsee N, Nakornpakdee Y, Sangjun N, Komanee P, Collin N, Ruxrungtham K and Patarakul K (2022) Front. Cell. Infect. Microbiol. 12:918629. doi: 10.3389/fcimb.2022.918629
The animal facility was misidentified in the Materials and Methods section.
A correction has been made to the section Materials and Methods, subsection Immunization and Challenge in Hamsters, paragraph 1:
The sentence originally read:
“Outbred golden Syrian hamsters were purchased from the North-East Animal Laboratory Center, Khon Kaen University, Thailand.”
It has been corrected to:
“Outbred golden Syrian hamsters were obtained from the Animal Unit, Faculty of Medicine, Khon Kaen University, Thailand, which served as the animal resource provider for this study.”
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Leptospira, immunoglobulin-like protein A, subunit vaccine, adjuvant formulation, neutral liposome, squalene-in-water emulsion, QS21 saponin, QuilA saponin
Citation: Techawiwattanaboon T, Courant T, Brunner L, Sathean-anan-kun S, Krangvichian P, Iadsee N, Nakornpakdee Y, Sangjun N, Komanee P, Collin N, Ruxrungtham K and Patarakul K (2025) Correction: Designing adjuvant formulations to promote immunogenicity and protective efficacy of Leptospira immunoglobulin-like protein a subunit vaccine. Front. Cell. Infect. Microbiol. 15:1656235. doi: 10.3389/fcimb.2025.1656235
Received: 29 June 2025; Accepted: 29 July 2025;
Published: 18 August 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Techawiwattanaboon, Courant, Brunner, Sathean-anan-kun, Krangvichian, Iadsee, Nakornpakdee, Sangjun, Komanee, Collin, Ruxrungtham and Patarakul. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kanitha Patarakul, S2FuaXRoYS5QYUBjaHVsYS5hYy50aA==; a3BhdGFyYWt1bEBnbWFpbC5jb20=